Bixiye
P11-20 Updated Bulletin: Commercial Inpatient Admission Notification Process Changes
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2461 - 2470 ee natiijooyinka 3167
Bixiye
QP12-20 Reminder for Referring Subscribers to Participating Providers
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP14-20 New Service Type Options for Inpatient Admission Notifications on Availity Portal
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP13-20 Blue Cross Blue Shield National Coordination of Care SM Overview
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP11-20 Pharmacy Benefit Exclusion for Budesonide-Formoterol Fumarate Dihydrate Aerosol
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP10-20 Pharmacy Benefit Exclusion for Xenleta TM, Asparlas TM, Ogivri TM and Tranexamic Acid/Sodium Chloride
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP9-20 Pharmacy Benefit Exclusion Healthcare Administered Drugs
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP15-20 Commercial Medical Drug Exclusion List Expanded to Include Avsola
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP8-20 Medical Drug Update for New to Market Golodirsen (Vyondys 53)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP1-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) Criteria: Palforzia and Viaskin Peanut (Peanut Allery Oral Immunotherapy)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020